Evifacotrep

Cat. No.: HY-132813

CAS No.: 2413739-88-3

Molecular Formula: $C_{18}H_{12}ClF_4N_5O_2$

Molecular Weight: 441.77

Target: TRP Channel

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (113.18 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2636 mL	11.3181 mL	22.6362 mL
	5 mM	0.4527 mL	2.2636 mL	4.5272 mL
	10 mM	0.2264 mL	1.1318 mL	2.2636 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Evifacotrep, a short transient receptor potential channel 5 and 4 (TRPC5/TRPC4) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5/TRPC4 with IC_{50}s ≤50 nM[1].

IC_{50} & Target

TRPC5[1]

In Vitro

Evifacotrep (1 μM; 24 h) inhibits cell growth in ICLN-1694 cells(HEK-TRExhTRPC4)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Evifacotrep (30 mg/kg; sc; once daily or twice daily for 10 days) results in reduced urinary albumin excretion on following injury with puromycinaminonucleoside (PAN)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WO2020061162

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA